drugset
drugset / Trial / NCT05490472

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

NCT05490472 ↗

Phase 1/2 Recruiting 102 enrolled Jacobio Pharmaceuticals Co., Ltd.
Non-randomizedSequentialOpen-labelTreatment

Summary

This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.

Timeline

Start
2022-12-20
Primary completion
2026-08
Completion
2027-08

Drugs

EvaluationDrugModalityDoseRoute
Subject JAB-2485 Unknown — Oral

Indications

estrogen-receptor positive breast cancer small cell lung carcinoma triple-negative breast carcinoma